Policy Shifts Encouraging Cost-Effective Rare Disease Drug Development
Developing therapies for rare diseases has long been a financial and scientific challenge for the pharmaceutical industry. With small patient populations, high research costs, and complex regulatory pathways, companies often struggle to create viable...
